| Study | Country | Design | Participants, characteristics in intervention group | Participants, characteristics in control group |
|---|
| Sample size (at allocation)/n | Age/year | Gender | Cancer type | Sample size (at allocation) /n | Age/year | Gender | Cancer type |
|---|
| BJÖRNEKLETT et al, 2013[8] | Sweden | ① | 191 | 57.8 (30‒84) | Female: 100% | Breast: 100% | 191 | 58.7 (38‒83) | Female: 100% | Breast: 100% | FAUSER et al, 2019[9-10] | Germany | ② | 229 | 50.8±7.1 | Female: 71.2% | Breast: 31.4%, digestive tract: 14.4%, lymphatic/related tissue: 15.3%, female genitalia: 15.3% | 255 | 50.3±7.9 | Female: 63.1% | Breast: 28.2%, digestive tract: 18.4%, lymphatic/related tissue: 14.9%, female genitalia: 10.6% | LEENSEN et al, 2017[11] | Netherlands | ④ | 93 | 47.9±7.4 | Female: 90.3% | Breast: 83.9%, colorectal: 8.6%, non-Hodgkin′s lymphoma: 5.4%, other: 2.2% | ‒ | ‒ | ‒ | ‒ | OLDERVOLL et al, 2013[12] | Norway | ③ | 56 | 51 (37‒66) | NR | Breast: 91%, gynecological: 9% | 60 | 50 (32‒67) | NR | Breast: 55%, gynecological: 45% | MOURGUES et al, 2014[13] | France | ① | 85 | 51.9±8.5 | Female: 100% | Breast: 100% | 67 | 51.9±10.3 | Female: 100% | Breast: 100% | RUSBRIDGE et al, 2013[14] | UK | ④ | 34 | 46±11 | Male: 59% | Brain: 100% | ‒ | ‒ | ‒ | ‒ | | STAPELFELDT et al, 2021[15] | Denmark | ① | 83 | 48.2 (44‒56) | Female: 91.6% | Breast: 78.3%, colonrectal: 13.3% | 264 | 50.0 (43.7‒54.6) | Female: 92.8% | Breast: 85.2%, colonrectal: 10.2% | TAMMINGA et al, 2013[16] | Netherlands | ① | 65 | 47.5±8.2 | Female: 99% | Breast: 64%, cervix: 23% | 68 | 47.6±7.8 | Female: 100% | Breast: 60%, cervix: 22% | TAMMINGA et al, 2019[17] | Netherlands | ① | 49 | 47.1±8.2 | Female: 98% | Breast: 61%, cervix: 22% | 57 | 47.8±7.6 | Female: 100% | Breast: 61%, cervix: 23% | THIJS et al, 2012[18] | Netherlands | ③ | 72 | 49±8.3 | Female: 88.9% | Breast: 70.8%, lymphoma: 13.8%, colorectal: 6.9% | 38 | 49±9.2 | Female: 76.3% | Breast: 68.4%, lymphoma: 18.5%, colorectal: 13.2% | THORSEN et al, 2016[19] | Norway | ④ | 106 | 48.8±8.6 | Female: 100% | Breast: 60.4%, gynaecological: 31.1% | ‒ | ‒ | ‒ | ‒ | ZAMAN et al, 2021[20] | Netherlands | ① | 42 | 54±7.7 | Male: 64% | Colonrectal: 88.1% | 46 | 56±6.6 | Male: 67% | Colonrectal: 84.8% |
|